CADL Candel Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Candel Therapeutics, Inc. (CADL) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on March 12, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Candel Therapeutics, Inc. (CADL) (SEC CIK 1841387), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 12, 2026 — details in Exhibit 99.1
- • Filing "furnished" not "filed," meaning results carry no Section 18 liability — standard for earnings releases
Item 8.01: Other Events
- • Offering raises ~$93.5M net proceeds, extending cash runway into Q1 2028
- • Underwriters hold option to purchase additional shares, potentially increasing total raise above $93.5M
Item 1.01: Entry into a Material Definitive Agreement
- • Offering priced at $5.45/share for 18,348,624 firm shares; underwriters hold 30-day option for 2,752,293 additional shares
- • Net proceeds ~$93.5M (or ~$107.6M if overallotment exercised fully) — meaningful cash infusion for a clinical-stage biotech
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Candel Therapeutics, Inc. (CADL) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 12, 2026 | — | Analysis | — |
10-K | Mar 12, 2026 | Dec 31, 2025 | — | |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Feb 19, 2026 | — | — | |
8-K | Dec 5, 2025 | — | — | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 14, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 13, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | — | |
10-Q | May 14, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 30, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 29, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 12, 2021 | Sep 30, 2021 | — | |
10-Q | Sep 8, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest CADL SEC filings in 2026?
Candel Therapeutics, Inc. (CADL) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on March 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CADL file its most recent 10-K annual report?
Candel Therapeutics, Inc. (CADL) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CADL 10-Q quarterly reports?
Candel Therapeutics, Inc. (CADL)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every CADL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CADL filed recently?
Candel Therapeutics, Inc. (CADL)'s most recent 8-K was filed on March 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CADL insider trading activity (Form 4)?
SignalX aggregates every CADL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CADL file with the SEC?
Candel Therapeutics, Inc. (CADL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CADL filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Candel Therapeutics, Inc. (CADL).
What is CADL's SEC CIK number?
Candel Therapeutics, Inc. (CADL)'s SEC CIK (Central Index Key) number is 1841387. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1841387 to look up all CADL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CADL return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Candel Therapeutics, Inc. (CADL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Candel Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 23+ filings.